Marco Rossi1,2, Lorenzo Gay1,2, Federico Ambrogi3, Marco Conti Nibali1,2, Tommaso Sciortino1,2, Guglielmo Puglisi1,2, Antonella Leonetti1,2, Cristina Mocellini4, Manuela Caroli5, Susanna Cordera6, Matteo Simonelli7, Federico Pessina7, Piera Navarria7, Andrea Pace8, Riccardo Soffietti9, Roberta Rudà9, Marco Riva1,2, Lorenzo Bello1,2. 1. Neurosurgical Oncology Unit, Dept of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy. 2. IRCCS Istituto Ortopedico Galeazzi, Neurosurgical Oncology Unit, Milano, Italy. 3. Laboratory of Medical Statistics, Biometry and Epidemiology "G.A.Maccararo," Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy. 4. Neuro-oncologia, Divisione di Neurologia, Ospedale Santa Croce e Carle, Cuneo, Italy. 5. Neurochirurgia, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, Italy. 6. Neuro-oncologia, Divisione di Neurologia, Ospedale Regionale Parini, Aosta, Italy. 7. Humanitas Cancer Center, Humanitas Research Hospital, IRCCS, Rozzano, Italy. 8. Neuro-Oncologia, Istituto Nazionale Tumori Regina Elena, Roma, Italy. 9. Neuro-Oncologia, Città della Salute e della Scienza, Università di Torino, Torino, Italy.
Abstract
BACKGROUND: Supratotal resection is advocated in lower-grade gliomas (LGGs) based on theoretical advantages but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecularly defined LGGs with oncological outcomes. METHODS: Included were 460 presumptive LGGs; 404 resected; 347 were LGGs, 319 isocitrate dehydrogenase (IDH)-mutated, 28 wildtype. All patients had clinical, imaging, and molecular data. Resection aimed at supratotal resection without any patient or tumor a priori selection. The association of extent of resection (EOR), categorized on volumetric fluid attenuated inversion recovery images as residual tumor volume, along with postsurgical management with progression-free survival (PFS), malignant (M)PFS, and overall survival (OS) assessed by univariate, multivariate, and propensity score analysis. The study mainly focused on IDH-mutated LGGs, the "typical LGGs." RESULTS: Median follow-up was 6.8 years (interquartile range, 5-8). Out of 319 IDH-mutated LGGs, 190 (59.6%) progressed, median PFS: 4.7 years (95% CI: 4-5.3). Total and supratotal resection obtained in 39% and 35% of patients with IDH1-mutated tumors. In IDH-mutated tumors, most patients in the partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months (95% CI: 25-36) in subtotal, 46 months (95% CI: 38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular subtypes and grade. At random forest analysis, PFS strongly associated with EOR, radiotherapy, and previous treatment. In the propensity score analysis, EOR associated with PFS (hazard ratio, 0.03; 95% CI: 0.01-0.13). MPFS occurred in 32.1% of subtotal total groups; 1 event in supratotal. EOR, grade III, previous treatment correlated to MPFS. At random forest analysis, OS associated with EOR as well. CONCLUSIONS: Supratotal resection strongly associated with PFS, MPFS, and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
BACKGROUND: Supratotal resection is advocated in lower-grade gliomas (LGGs) based on theoretical advantages but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecularly defined LGGs with oncological outcomes. METHODS: Included were 460 presumptive LGGs; 404 resected; 347 were LGGs, 319 isocitrate dehydrogenase (IDH)-mutated, 28 wildtype. All patients had clinical, imaging, and molecular data. Resection aimed at supratotal resection without any patient or tumor a priori selection. The association of extent of resection (EOR), categorized on volumetric fluid attenuated inversion recovery images as residual tumor volume, along with postsurgical management with progression-free survival (PFS), malignant (M)PFS, and overall survival (OS) assessed by univariate, multivariate, and propensity score analysis. The study mainly focused on IDH-mutated LGGs, the "typical LGGs." RESULTS: Median follow-up was 6.8 years (interquartile range, 5-8). Out of 319 IDH-mutated LGGs, 190 (59.6%) progressed, median PFS: 4.7 years (95% CI: 4-5.3). Total and supratotal resection obtained in 39% and 35% of patients with IDH1-mutated tumors. In IDH-mutated tumors, most patients in the partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months (95% CI: 25-36) in subtotal, 46 months (95% CI: 38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular subtypes and grade. At random forest analysis, PFS strongly associated with EOR, radiotherapy, and previous treatment. In the propensity score analysis, EOR associated with PFS (hazard ratio, 0.03; 95% CI: 0.01-0.13). MPFS occurred in 32.1% of subtotal total groups; 1 event in supratotal. EOR, grade III, previous treatment correlated to MPFS. At random forest analysis, OS associated with EOR as well. CONCLUSIONS: Supratotal resection strongly associated with PFS, MPFS, and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
Authors: Marco Rossi; Sepehr Sani; Marco Conti Nibali; Luca Fornia; Lorenzo Bello; Richard W Byrne Journal: Neurosurg Clin N Am Date: 2019-01 Impact factor: 2.509
Authors: David E Reuss; Yasin Mamatjan; Daniel Schrimpf; David Capper; Volker Hovestadt; Annekathrin Kratz; Felix Sahm; Christian Koelsche; Andrey Korshunov; Adriana Olar; Christian Hartmann; Jaap C Reijneveld; Pieter Wesseling; Andreas Unterberg; Michael Platten; Wolfgang Wick; Christel Herold-Mende; Kenneth Aldape; Andreas von Deimling Journal: Acta Neuropathol Date: 2015-05-12 Impact factor: 17.088
Authors: David Schiff; Martin Van den Bent; Michael A Vogelbaum; Wolfgang Wick; C Ryan Miller; Martin Taphoorn; Whitney Pope; Paul D Brown; Michael Platten; Rakesh Jalali; Terri Armstrong; Patrick Y Wen Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Philip C De Witt Hamer; Santiago Gil Robles; Aeilko H Zwinderman; Hugues Duffau; Mitchel S Berger Journal: J Clin Oncol Date: 2012-04-23 Impact factor: 44.544
Authors: Patrick Y Wen; Susan M Chang; Martin J Van den Bent; Michael A Vogelbaum; David R Macdonald; Eudocia Q Lee Journal: J Clin Oncol Date: 2017-06-22 Impact factor: 44.544
Authors: A S Jakola; A J Skjulsvik; K S Myrmel; K Sjåvik; G Unsgård; S H Torp; K Aaberg; T Berg; H Y Dai; K Johnsen; R Kloster; O Solheim Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Tamara Ius; Sam Ng; Jacob S Young; Barbara Tomasino; Maurizio Polano; David Ben-Israel; John J P Kelly; Miran Skrap; Hugues Duffau; Mitchel S Berger Journal: Neuro Oncol Date: 2022-04-01 Impact factor: 13.029
Authors: Ingo K Mellinghoff; Susan M Chang; Kurt A Jaeckle; Martin van den Bent Journal: Hematol Oncol Clin North Am Date: 2021-10-25 Impact factor: 2.861
Authors: Gabrielle Metz; Dasantha Jayamanne; Helen Wheeler; Matthew Wong; Raymond Cook; Nicholas Little; Jonathon Parkinson; Marina Kastelan; Chris Brown; Michael Back Journal: BMC Neurol Date: 2022-01-13 Impact factor: 2.474
Authors: Antonella Leonetti; Guglielmo Puglisi; Marco Rossi; Luca Viganò; Marco Conti Nibali; Lorenzo Gay; Tommaso Sciortino; Henrietta Howells; Luca Fornia; Marco Riva; Gabriella Cerri; Lorenzo Bello Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244
Authors: Marco Riva; Tommaso Sciortino; Riccardo Secoli; Ester D'Amico; Sara Moccia; Bethania Fernandes; Marco Conti Nibali; Lorenzo Gay; Marco Rossi; Elena De Momi; Lorenzo Bello Journal: Cancers (Basel) Date: 2021-03-03 Impact factor: 6.639